LXRX Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Lexicon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.80 |
| 52 Week High | US$3.73 |
| 52 Week Low | US$0.73 |
| Beta | 1.24 |
| 11 Month Change | -56.73% |
| 3 Month Change | -55.28% |
| 1 Year Change | -27.49% |
| 33 Year Change | -82.43% |
| 5 Year Change | -78.65% |
| Change since IPO | -99.39% |
Recent News & Updates
Recent updates
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
Oct 16Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Aug 03Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
May 28Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
Mar 12Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do
Jan 26Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Shareholder Returns
| LXRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.3% | 4.0% | 2.0% |
| 1Y | -27.5% | 18.0% | 32.4% |
Return vs Industry: LXRX underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: LXRX underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| LXRX volatility | |
|---|---|
| LXRX Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LXRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LXRX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 285 | Mike Exton | www.lexpharma.com |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc. Fundamentals Summary
| LXRX fundamental statistics | |
|---|---|
| Market cap | US$296.50m |
| Earnings (TTM) | -US$216.39m |
| Revenue (TTM) | US$5.23m |
55.6x
P/S Ratio-1.3x
P/E RatioIs LXRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LXRX income statement (TTM) | |
|---|---|
| Revenue | US$5.23m |
| Cost of Revenue | US$72.90m |
| Gross Profit | -US$67.67m |
| Other Expenses | US$148.73m |
| Earnings | -US$216.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | -1,294.05% |
| Net Profit Margin | -4,138.32% |
| Debt/Equity Ratio | 56.0% |
How did LXRX perform over the long term?
See historical performance and comparison